Zenas BioPharma, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q3 2023 to Q3 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Zenas BioPharma, Inc. quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q3 2023 to Q3 2024.
- Zenas BioPharma, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2024 was -$38.7M, a 209% decline year-over-year.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)